ANI PHARMACEUTICALS INC — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax Withholding | 627 | $61.89 | $38,805 | 45,465 | Feb 28, 2025 |
| Mutz Christopher | HEAD OF RARE DISEASE | Tax Withholding | 1,275 | $61.89 | $78,910 | 114,191 | Feb 28, 2025 |
| Lalwani Nikhil | PRESIDENT & CEO | Tax Withholding | 12,216 | $61.89 | $756,048 | 502,694 | Feb 28, 2025 |
| Gutwerg Ori | SVP, GENERICS | Tax Withholding | 1,570 | $61.89 | $97,167 | 99,176 | Feb 28, 2025 |
| Davis Krista | SVP, CHIEF HR OFFICER | Tax Withholding | 1,099 | $61.89 | $68,017 | 67,525 | Feb 28, 2025 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax Withholding | 1,099 | $61.89 | $68,017 | 80,945 | Feb 28, 2025 |
| CAREY STEPHEN P. | SVP & CFO | Tax Withholding | 1,861 | $61.89 | $115,177 | 192,223 | Feb 28, 2025 |
| Davis Krista | SVP, CHIEF HR OFFICER | Sale | 1,000 | $60.20 | $60,200 | 68,624 | Feb 21, 2025 |
| Mutz Christopher | HEAD OF RARE DISEASE | Award / Grant | 16,538 | — | — | 118,123 | Feb 15, 2025 |
| Gutwerg Ori | SVP, GENERICS | Award / Grant | 10,444 | — | — | 103,339 | Feb 15, 2025 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Award / Grant | 9,574 | — | — | 92,588 | Feb 12, 2025 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax Withholding | 582 | $58.92 | $34,291 | 46,092 | Feb 12, 2025 |
| Lalwani Nikhil | PRESIDENT & CEO | Award / Grant | 60,932 | — | — | 522,709 | Feb 12, 2025 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | Award / Grant | 14,362 | — | — | 64,041 | Feb 12, 2025 |
| Davis Krista | SVP, CHIEF HR OFFICER | Award / Grant | 8,704 | — | — | 70,820 | Feb 12, 2025 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax Withholding | 1,434 | $58.92 | $84,491 | 82,044 | Feb 12, 2025 |
| CAREY STEPHEN P. | SVP & CFO | Award / Grant | 16,538 | — | — | 195,814 | Feb 12, 2025 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 400 | $53.92 | $21,568 | 55,588 | Jan 13, 2025 |
| CAREY STEPHEN P. | SVP & CFO | Sale | 7,500 | $55.79 | $418,425 | 154,468 | Dec 17, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $56.24 | $14,060 | 55,988 | Dec 13, 2024 |
| Davis Krista | SVP, CHIEF HR OFFICER | Sale | 1,000 | $60.00 | $60,000 | 49,059 | Dec 11, 2024 |
| Lalwani Nikhil | PRESIDENT & CEO | Sale | 3,481 | $58.30 | $202,942 | 370,378 | Nov 26, 2024 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax Withholding | 867 | $56.58 | $49,055 | 33,169 | Nov 15, 2024 |
| Mutz Christopher | HEAD OF RARE DISEASE | Sale | 6,500 | $57.70 | $375,050 | 76,777 | Nov 15, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $61.36 | $15,340 | 56,238 | Nov 13, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $57.19 | $14,298 | 56,488 | Oct 14, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $56.82 | $14,205 | 56,738 | Sep 13, 2024 |
| Davis Krista | SVP, CHIEF HR OFFICER | Tax Withholding | 1,486 | $56.15 | $83,439 | 50,059 | Sep 12, 2024 |
| Lalwani Nikhil | PRESIDENT & CEO | Tax Withholding | 3,646 | $60.51 | $220,619 | 373,859 | Sep 8, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $59.62 | $14,905 | 56,988 | Aug 13, 2024 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sale | 2,743 | $62.00 | $170,066 | 632,620 | Jul 18, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax Withholding | 1,743 | $61.35 | $106,933 | 57,238 | Jul 18, 2024 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sale | 22,000 | $64.27 | $1,413,940 | 649,620 | Jul 15, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $64.91 | $16,228 | 58,981 | Jul 12, 2024 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sale | 20,000 | $63.44 | $1,268,800 | 193,226 | Jul 1, 2024 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sale | 20,000 | $58.90 | $1,178,000 | 682,620 | Jun 21, 2024 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sale | 11,447 | $59.86 | $685,217 | 702,620 | Jun 17, 2024 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sale | 250 | $63.80 | $15,950 | 59,231 | Jun 13, 2024 |
| Marken James G. | SVP OPS & PROD DEV | Tax Withholding | 11,087 | $67.70 | $750,590 | 117,829 | Jun 7, 2024 |
| Gutwerg Ori | SVP, GENERICS | Sale | 2,985 | $67.00 | $199,995 | 77,227 | Jun 5, 2024 |
| CAREY STEPHEN P. | SVP & CFO | Sale | 5,000 | $63.58 | $317,900 | 161,968 | Jun 4, 2024 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sale | 20,000 | $64.41 | $1,288,200 | 213,226 | Jun 3, 2024 |
| Walsh Patrick D | — | Award / Grant | 4,410 | — | — | 74,712 | May 21, 2024 |
| Thoma Jeanne | — | Award / Grant | 4,410 | — | — | 40,609 | May 21, 2024 |
| TANNENBAUM RENEE P | — | Award / Grant | 4,410 | — | — | 22,621 | May 21, 2024 |
| Pera Antonio R | — | Award / Grant | 4,410 | — | — | 31,037 | May 21, 2024 |
| Leonard Matthew J | — | Award / Grant | 4,410 | — | — | 11,993 | May 21, 2024 |
| HAUGHEY THOMAS | — | Award / Grant | 4,410 | — | — | 51,526 | May 21, 2024 |
| Mutz Christopher | HEAD OF RARE DISEASE | Sale | 2,000 | $61.61 | $123,220 | 83,277 | May 21, 2024 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sale | 12,855 | $61.81 | $794,568 | 732,620 | May 20, 2024 |